Highest-materiality recent filing
Travere Therapeutics CAO Sandra Calvin to retire; John Torell to succeed
Sandra Calvin to retire as CAO/PAO after filing 10-K expected in February 2027.
Travere CRO William Rote to retire Feb 2027; CMO Inrig promoted to EVP, Head of R&D
William Rote, Ph.D., Chief Research Officer, to retire effective Feb 17, 2027, after 10 years.
Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones
Exclusive license for civorebrutinib (BTK inhibitor) outside China and select East/Southeast Asia countries.
Travere shareholders approve 3M share increase under 2018 equity plan
Stockholders approved amendment to 2018 Plan, increasing authorized shares by 3,000,000 shares.
Closed offering of $525M aggregate principal of 0.50% Convertible Senior Notes due 2032; net proceeds est. $508.5M.
Travere Q1 net product sales up 64% to $124.5M; FILSPARI approved for FSGS
FILSPARI net sales $105.2M (+88% YoY); 993 new PSFs in IgAN during Q1.
FDA approves Travere's FILSPARI for FSGS without nephrotic syndrome, expanding label beyond IgAN
FDA approved FILSPARI (sparsentan) for FSGS without nephrotic syndrome in patients aged 8+, second indication.
Travere reports Q4 net income of $2.7M; FILSPARI sales up 108% YoY to $103.3M
FILSPARI U.S. net product sales $103.3M in Q4 2025 (+108% YoY); full year $322M (+144%).
FDA extends FILSPARI FSGS sNDA PDUFA to April 13, 2026; cites Major Amendment
FDA extended PDUFA target action date to April 13, 2026, after determining supplemental NDA responses constitute a Major Amendment.
Travere reports record Q4 FILSPARI sales of $103M; FSGS PDUFA decision due Jan 13
Preliminary Q4 2025 total U.S. net product sales ~$127M; FILSPARI sales ~$103M (+108% YoY).
Travere reports Q3 net income of $25.7M; FILSPARI sales up 155% YoY to $90.9M
U.S. FILSPARI net product sales $90.9M (+155% YoY); 731 new patient start forms in Q3.
FDA says no advisory committee needed for FILSPARI sNDA in FSGS; PDUFA Jan 13, 2026
FDA informed Travere that an advisory committee is no longer needed for the FILSPARI (sparsentan) sNDA for FSGS.
Travere Q2 2025: FILSPARI sales $71.9M (+165% YoY); net loss narrows to $12.8M
U.S. FILSPARI net product sales $71.9M, up 165% YoY; 745 new patient start forms received in Q2.
Travere stockholders approve 4M-share increase in 2018 equity plan at annual meeting
Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000 (71,802,001 votes for).
FDA accepts Travere's sNDA for FILSPARI in FSGS; PDUFA Jan 13, 2026
FDA accepted sNDA for traditional approval of FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS).
FILSPARI U.S. net product sales $55.9M in Q1 2025, up 182% YoY; 703 new patient start forms received.
Travere Q1 net product sales $75.9M; FILSPARI sales $55.9M, net loss narrows to $0.47/share
Net product sales $75.9M (1Q25) vs $40.0M (1Q24), driven by FILSPARI launch.
Travere's FILSPARI gets standard EU marketing authorization; receives $17.5M milestone
European Commission converts conditional approval to standard MA for FILSPARI (sparsentan) for primary IgAN in all EU member states, plus Iceland, Liechtenstein, Norway.
Travere submits sNDA to FDA seeking priority review for FILSPARI in FSGS
Submitted sNDA on March 17, 2025 seeking priority review for traditional approval of FILSPARI (sparsentan) for FSGS.
Travere Q4 FILSPARI sales $49.6M; plans FSGS sNDA by end Q1 2025
Q4 total net product sales $73.5M (FILSPARI $49.6M); FY total $226.7M (FILSPARI $132.2M).
Travere plans sNDA for FILSPARI in FSGS after FDA Type C meeting
Completed Type C meeting with FDA; sNDA seeking traditional approval for FILSPARI in FSGS expected by end of Q1 2025.
Travere reports ~$74M preliminary Q4 net product sales; FILSPARI PSFs up 40% QoQ
Preliminary Q4 2024 FILSPARI net sales ~$50M; total Q4 net product sales ~$74M; FY2024 ~$227M.
Travere Therapeutics prices $125M public offering of 7.8M shares at $16.00/share
Priced 7,812,500 shares at $16.00 per share; gross proceeds of $125.0M.
Travere reports Q3 net loss $54.8M; FILSPARI sales $35.6M, full FDA approval in IgAN
Net product sales $61.0M (FILSPARI $35.6M); 505 new PSFs in Q3; 2,989 total since launch.
Voluntary pause of enrollment in Phase 3 HARMONY Study for pegtibatinase (classical homocystinuria).
FDA grants full approval to Travere's FILSPARI for IgA nephropathy based on PROTECT study
FDA full approval for FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN at risk of disease progression.
Travere Q2 FILSPARI sales $27.1M, up 37% Q/Q; 521 new patient start forms
Net product sales $52.2M (incl. $27.1M FILSPARI); total revenue $54.1M.
All ten director nominees elected; John A. Orwin received 43.7M for vs 14.9M withheld.
Travere Q1: FILSPARI sales $19.8M; FDA Priority Review for full approval by Sept 5
Net product sales $40.0M (Q1 2024), up from $24.2M YoY, driven by FILSPARI launch.
EU grants conditional marketing authorization for Travere's FILSPARI in IgA nephropathy
European Commission approved FILSPARI (sparsentan) for adults with primary IgAN with urine protein excretion ≥1.0 g/day or UPCR ≥0.75 g/g.
Travere and CSL Vifor receive CHMP positive opinion for sparsentan in IgAN in EU
EMA CHMP recommended conditional marketing authorization for sparsentan for primary IgAN with proteinuria >1.0 g/day.
Travere Q4 net product sales $39.9M, FILSPARI PSFs total 1,452 in 2023; sNDA filing imminent
Net product sales of $39.9M in Q4 2023 ($127.5M FY); driven by FILSPARI launch ($14.7M Q4).
Travere reports preliminary Q4 2023 net product sales ~$40M, FILSPARI sales $15M; cash $567M
Preliminary Q4 2023 net product sales from continuing ops ~$40M; FY 2023 ~$128M.
Travere announces successful pre-NDA for FILSPARI in IgAN, FSGS setback, and 20% workforce reduction
Successful pre-NDA meeting for FILSPARI in IgA nephropathy; sNDA submission for full approval planned for Q1 2024.
Travere Q3 net income $150.7M from bile acid sale; FILSPARI sales $8M, 430 new starts
Net income $150.7M ($1.97/share) includes gain from bile acid portfolio sale; prior year loss $69.7M.
Travere's FILSPARI misses eGFR total slope endpoint but achieves chronic slope significance in IgAN
eGFR total slope difference vs irbesartan 1.0 mL/min/1.73m2 per year, p=0.058 (missed statistical significance).
Net cash proceeds of $210M at close plus up to $235M in milestones from sale of Chenodal/Cholbam to Mirum; estimated gain of $235M.
Travere closes $210M asset sale to Mirum; eligible for up to $235M in milestones
Upfront cash payment of $210M from Mirum for Chenodal and Cholbam assets.
Travere reports Q2 loss, FILSPARI launch progress, and $445M bile acid portfolio sale
Net loss $85.6M ($1.13/share) vs $67M loss in prior year; revenue $59.7M from product sales $57M and licensing.
Travere sells Chenodal and Cholbam assets to Mirum for up to $445M cash
Total consideration up to $445M: $210M at closing plus up to $235M in milestone payments tied to net sales.
Travere reports positive Phase 1/2 COMPOSE Cohort 6 data for pegtibatinase in HCU
Pegtibatinase 2.5 mg/kg twice weekly reduced total homocysteine (tHcy) by mean 67.1% vs placebo increase of 0.6%.
Travere stockholders approve 2.7M share increase to 2018 equity incentive plan
Stockholders approved amendment increasing authorized shares under 2018 Equity Incentive Plan by 2,700,000 shares.
Travere Q1 net loss $86.3M; FILSPARI launch nets $3M in 6 weeks
Net product sales $50.3M (incl. $3M FILSPARI), up from $46.4M YoY; net loss $86.3M ($1.27/share) vs $76M ($1.20).
eGFR total slope difference 0.3 mL/min/1.73m2/yr favoring sparsentan (p=0.7491), not statistically significant.
BDO dismissed as independent auditor effective April 6, 2023; EY appointed for fiscal year ending Dec 31, 2023.
Travere Therapeutics prices $200M public offering of common stock and pre-funded warrants
Offering of 8,275,000 shares at $21.00/share and 1,250,000 pre-funded warrants at $20.9999 each.
Travere reports Q4 2022 net loss $65.8M; FDA granted accelerated approval for FILSPARI in IgAN
Net product sales $52.3M in Q4 2022 vs $54.6M in Q4 2021; full year $200.5M vs $210.8M.
FDA grants accelerated approval to Travere's FILSPARI for IgA nephropathy
FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression; continued approval contingent on confirmatory data.
Travere reports preliminary Q4 rev ~$52M; sparsentan PDUFA Feb 17, 2023
Preliminary net product sales Q4 2022 ~$52M; full year 2022 net product sales ~$201M, total revenue $212M.
Travere Q3 net loss $69.7M; PDUFA for sparsentan extended to Feb 17, 2023; EMA accepts CMA
Net loss $69.7M ($1.09/share) vs $35.6M ($0.59) YoY; adjusted net loss $48.9M ($0.76).
Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.
On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027
On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022
Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of September 1, 2022.
Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of the Officer Resignation Date.
On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022
On October 12, 2021, Travere Therapeutics, Inc. (the “Company”) announced that its chief medical officer, Noah Rosenberg, M.D., will be transitioning to an executive advisor role at the end of 2021.
On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved the appointment of Sandra Calvin as the Company’s principal accounting officer, effective September 15, 2021.
On September 14, 2021, the Board of Directors (the “Board”) of Travere Therapeutics, Inc. (the “Company”) approved an increase in the size of the Board of Directors from 10 to 11 members and elected Ruth Williams-Brinkley to serve as a director of the Company, effective September 14, 2021.
Max materiality 0.90 · Median 0.75 · Most common event earnings